{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:07:00Z","timestamp":1791356820040,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"Leo Pharma AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jaad.2024.04.026","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:11:32Z","timestamp":1713694292000},"page":"300-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry"],"prefix":"10.1016","volume":"91","author":[{"given":"Junfen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Boesjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Loman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esm\u00e9","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet L.E.","family":"Romeijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte S.","family":"Spekhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian F.","family":"van der Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coco C.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa P.","family":"van der Rijst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"van Lumig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke M.T.","family":"van Lynden-van Nes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.","family":"Tupker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annieke","family":"Nijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annebeth","family":"Flinterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaziena","family":"Politiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter R.H.","family":"Touwslager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wianda A.","family":"Christoffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiarra M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Kamsteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-4382","authenticated-orcid":false,"given":"Marie-Louise A.","family":"Schuttelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jaad.2024.04.026_bib1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10086","key":"10.1016\/j.jaad.2024.04.026_bib2","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2024.04.026_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.04.026_bib5","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jaad.2024.04.026_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","article-title":"Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study","volume":"158","author":"Strober","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.04.026_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.04.026_bib8","article-title":"Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib9","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1111\/jdv.18648","article-title":"A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"37","author":"Stingeni","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.04.026_bib10","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1080\/09546634.2022.2043545","article-title":"Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2024.04.026_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jdv.18849","article-title":"A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis","volume":"37","author":"Vittrup","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2024.04.026_bib12","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/jdv.18450","article-title":"Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice","volume":"36","author":"Lasek","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.04.026_bib13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","article-title":"Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, The Netherlands) registry","volume":"83","author":"Bosma","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.04.026_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdin.2021.06.001","article-title":"Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study","volume":"4","author":"Georgakopoulos","year":"2021","journal-title":"JAAD Int"},{"issue":"6","key":"10.1016\/j.jaad.2024.04.026_bib16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.04.026_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.04.026_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.04.026_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00403-021-02185-3","article-title":"Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis","volume":"313","author":"Silverberg","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.jaad.2024.04.026_bib21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s13555-021-00558-0","article-title":"Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials","volume":"11","author":"Griffiths","year":"2021","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.04.026_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jaad.2024.04.026_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.04.026_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.04.026_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","article-title":"Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study","volume":"127","author":"Chovatiya","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaad.2021.10.058","article-title":"DESCRIBE-AD: a novel classification framework for atopic dermatitis","volume":"87","author":"Chovatiya","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.04.026_bib27","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.5382","article-title":"The treat-to-target project in atopic dermatitis: one year on","volume":"103","author":"De Bruin-Weller","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11121-007-0070-9","article-title":"How many imputations are really needed? Some practical clarifications of multiple imputation theory","volume":"8","author":"Graham","year":"2007","journal-title":"Prev Sci"},{"issue":"10","key":"10.1016\/j.jaad.2024.04.026_bib29","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3886","article-title":"Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay registry","volume":"101","author":"Ari\u00ebns","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2024.04.026_bib30","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.04.026_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02950-4","article-title":"A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world","volume":"11","author":"Jang","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jaad.2024.04.026_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ajd.14196","article-title":"Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis","volume":"65","author":"Mel\u00e9-Ninot","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.04.026_bib33","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2024.04.026_bib34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","article-title":"Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay registry","volume":"158","author":"Spekhorst","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.04.026_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.19577","article-title":"Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients","volume":"184","author":"Nettis","year":"2021","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.04.026_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13887","article-title":"Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry","volume":"33","author":"Kamphuis","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2024.04.026_bib37","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/all.15717","article-title":"Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis","volume":"78","author":"Achten","year":"2023","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.jaad.2024.04.026_bib38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","article-title":"Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Soria","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.04.026_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","article-title":"Characterizing dupilumab facial redness: a multi-institution retrospective medical record review","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.04.026_bib40","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"10209","key":"10.1016\/j.jaad.2024.04.026_bib41","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.04.026_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.992731","article-title":"Dupilumab efficacy and safety in patients with moderate to severe asthma: a systematic review and meta-analysis","volume":"13","author":"Zaazouee","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224006418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224006418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:25:07Z","timestamp":1722007507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224006418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0190962224006418"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.04.026","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}